Trial Profile
Retrospective, interventional study of ranibizumab in neovascular age-related macular degeneration patients with phakic and pseudophakic eyes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 08 Dec 2015 New trial record